Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pituitary Diseases Clear all
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT05775523
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Evaluation and Treatment of Neurosurgical Disorders

NCT00060541
View directory record Official record
Conditions
Neurologic Disorders
Interventions
Laboratory tests, Radiological exams
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
4 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Completed No phase listed Observational

Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03500913
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT03364803
View directory record Official record
Conditions
Cushing's Disease, Cushing Syndrome, Cushing Disease
Interventions
Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Barratt's Impulsivity Scale (BIS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), State Food Craving Questionnaire-State (FCQ-S), Trait Food Craving Questionnaire-Trait (FCQ-T), Visual Analogue Scale (VAS), Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
14 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 29, 2026, 1:41 AM EDT
Completed No phase listed Observational Results available

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211
View directory record Official record
Conditions
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions
combined oral contraceptives
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 29, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997

NCT00950781
View directory record Official record
Conditions
Menopause
Interventions
ACTH
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 29, 2026, 1:41 AM EDT
Completed No phase listed Observational

Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

NCT00004363
View directory record Official record
Conditions
Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
Interventions
chlorpropamide, desmopressin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
6 Months to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 29, 2026, 1:41 AM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

NCT03344458
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

NCT03548415
View directory record Official record
Conditions
Acromegaly
Interventions
IONIS-GHR-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 29, 2026, 1:41 AM EDT
Terminated No phase listed Observational

Constructing an Insulin-Like Growth Factor-based Prediction Model

NCT00263445
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
3 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 29, 2026, 1:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Growth Hormone's Effect on the Cardiovascular System

NCT00397319
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

Treatment for Endogenous Cushing's Syndrome

NCT01838551
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 29, 2026, 1:41 AM EDT
Completed No phase listed Observational Results available

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

NCT02310269
View directory record Official record
Conditions
Cushings Disease
Interventions
Pasireotide
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide sub-cutaneous
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

NCT03774446
View directory record Official record
Conditions
Cushing Disease
Interventions
Seliciclib
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

NCT03831880
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Genotropin, somatrogon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 29, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

NCT00704262
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

NCT04543253
View directory record Official record
Conditions
Cushing Syndrome
Interventions
MUSE biofeedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 1:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 29, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery

NCT05659524
View directory record Official record
Conditions
Pituitary Tumor
Interventions
Nasal saline irrigation
Other
Lead sponsor
Lori Wood
Other
Eligibility
19 Years to 85 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 29, 2026, 1:41 AM EDT